Sort
15,842 grants matching “pancreatic cancer”
Role of Ca2+/Calcineurin Signaling in S. Cerevisiae
$436,602Martha S Cyert · Stanford University · R01 · FY2010 · GM
Chemical pancreatectomy for chronic pancreatitis and pancreatic cancer
$436,569George K. Gittes · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · DK
Epigenetic Drivers of Cancer Progression
$436,565Andrew P Feinberg · Johns Hopkins University · R01 · FY2014 · CA
Precision Management of Cystic Precursors to Pancreatic Cancer
$436,460Pari Vijay Pandharipande · Ohio State University · R01 · FY2022 · CA
The role of wild-type KRAS in the context of tumor profession and metastasis
$436,453Gloria Huei-Ting Su · Columbia University Health Sciences · R01 · FY2016 · CA
Targeting Metabolic Crosstalk in Pancreatic Cancer
$436,431Christopher J. Halbrook · University Of California-Irvine · R37 · FY2024 · CA
Functions of SMAD4 in development and cancers
$436,301Chuxia Deng · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2009 · DK
Epigenetic drivers of cancer progression
$436,213Andrew P Feinberg · Johns Hopkins University · R01 · FY2020 · CA
Reprogramming the pancreatic tumor microenvironment with immunotherapy
$436,026Lei Zheng · Johns Hopkins University · R01 · FY2018 · CA
Targeted Radiation Therapy for Pancreatic Cancer
$435,945Surinder Kumar Batra · University Of Nebraska Medical Center · R01 · FY2018 · CA
Targeted Radiation Therapy for Pancreatic Cancer
$435,945Surinder Kumar Batra · University Of Nebraska Medical Center · R01 · FY2017 · CA
Targeted Radiation Therapy for Pancreatic Cancer
$435,945Surinder Kumar Batra · University Of Nebraska Medical Center · R01 · FY2015 · CA
Targeted Radiation Therapy for Pancreatic Cancer
$435,945Surinder Kumar Batra · University Of Nebraska Medical Center · R01 · FY2016 · CA
Exploitation of RAS signaling to develop therapy and early detection strategies for PDA
$435,921Rolf A Brekken · Ut Southwestern Medical Center · R01 · FY2016 · CA
Project 2: Immune signals promoting pancreas cancer stemness and progression
$435,882Mara H. Sherman · Stanford University · P01 · FY2021 · CA
The Chronic Pancreatitis Clinical Research Consortium
$435,853Christopher E Forsmark · University Of Florida · U01 · FY2025 · DK
Exploiting synthetic lethality to enhance KRAS inhibitor therapy of cancer
$435,827Benjamin G. Neel · New York University School Of Medicine · R21 · FY2025 · CA
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy
$435,761David G Denardo · Washington University · R01 · FY2023 · CA
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy
$435,761David G Denardo · Washington University · R01 · FY2022 · CA
Anti-tumor potential of temperature-sensitive p53 mutants
$435,695Jiandong Chen · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome [IND 121109 acknowledged 8/27/14]
$435,569Eric Hollander · Albert Einstein College Of Medicine · R01 · FY2018 · FD
PROSPECTIVE STUDY OF PANCREATIC CANCER PATHOGENESIS
$435,532Brigham And Women'S Hospital · R01 · FY2000 · CA
Epigenetic drivers of cancer progression
$435,427Andrew P Feinberg · Johns Hopkins University · R01 · FY2023 · CA
NF-kB Regulation of the Muscle Microenvironment in Cancer Cachexia
$435,203Denis C Guttridge · Medical University Of South Carolina · R01 · FY2020 · AR
Endoplasmic Reticulum Stress in the function of cancer associated fibroblasts in pancreatic cancer
$435,144Dãbora Barbosa Vendramini Costa · Henry Ford Health + Michigan State University Health Sciences · R01 · FY2025 · CA